Listed

XBiotech Inc.: Form 10-Q for the period ended Sep 30, 2019

Filed with the SEC on Nov 12, 2019 and accepted by EDGAR at Nov 12, 2019, 11:47 ET.

Share

Management's discussion and analysis

As filed, 21,461 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Overview

XBiotech Inc. (“XBiotech” or the “Company) is a pre-market biopharmaceutical company engaged in discovering and developing True Human™ monoclonal antibodies for treating a variety of diseases. True Human™ monoclonal antibodies are those which occur naturally in human beings—as opposed to being derived from animal immunization or otherwise engineered. We believe that naturally occurring monoclonal antibodies have the potential to be safer and more effective than their non-naturally occurring counterparts. XBiotech is focused on developing its True Human™ pipeline and manufacturing system.

We have never been profitable and, as of September 30, 2019, we had an accumulated deficit of $255.6 million. We had net losses of $6.2 million and $17.9 million for the three months and nine months ended September 30, 2019, respectively, compared to $5.1 million and $15.0 million for the three months and nine months ended September 30, 2018, respectively. We expect to incur significant and increasing operating losses for the foreseeable future as we advance our drug candidates from discovery through preclinical testing and clinical trials and seek regulatory approval and eventual commercialization. In addition to these increasing research and development expenses, we expect general and administrative costs to increase as we add personnel and continue to operate as a public company. We will need to generate significant revenues to achieve profitability, and we may never do so. As of September 30, 2019, we had 58 employees.

Recent Events:

The Company launched a randomized, double blind, placebo-controlled, multi-center phase 2 studies evaluating bermekimab subcutaneous formulation in adults with moderate to severe Hidradenitis Suppurativa (HS). The study, chaired by reknown dermatologist Dr. Alice Gottlieb, will involve150 patients into three arms: two bermekimab dosing regimens versus a placebo arm over sixteen (16) weeks of therapy. The study’s primary endpoint is the percentage of subjects achieving Hidradenitis Suppurativa Clinical Response (HiSCR) at week 12. Multiple secondary efficacy endpoints will be assessed after 12 and 16 weeks of therapy (for more information on this study please visit www.clinicaltrials.gov (http://www.clinicaltrials.gov)). This will be the third study undertaken by the Company in this indication. Results from an earlier, smaller randomized study are published in the Journal of Investigative Dermatology. This study met its primary endpoint, demonstrating significant improvement of HiSCR in patients treated with bermekimab compared to control after 12 weeks of therapy (response rate of 60% vs 10%, respectively (p=0.035)).

The Company also launched a randomized, double blind, placebo-controlled, multi-center phase 2 studies evaluating bermekimab subcutaneous formulation in adults with moderate to severe and Atopic Dermatitis (AD). The study, chaired by Dr. Seth Forman, is expected to have its first patient enrolled around the time of release of this filing and will involve 90 patients into three arms: two bermekimab dosing regimens versus a placebo arm over sixteen (16) weeks of therapy. In October, the Company presented results of an ealier open-label study with bermekimab in atopic dermatitis at the European Academy of Dermatology and Venereology (EADV) Congress, a leading annual dermatology conference. A highlight of the presented data was the observation that after only 8 weeks of bermekimab therapy, three-fourths of patients achieved 75% improvement in their Eczema Area and Severity Index (EASI 75) scores, which is a key assessment of response to therapy in AD. The current standard of care and the only approved biological therapy for AD involves a 16 week treatment regimen, and their clinical trials have shown to result in 44-51% of patients achieving 75% improvement in EASI score. In addition, Dr. Gottlieb presented signficant reduction in itch, with 75% of patients achieving clinically significant improvement in 8 weeks.

The Company also announced enrollment of the first patient in a phase 2, randomized double-blind, placebo-controlled clinical study evaluating bermekimab therapy in adults with systemic sclerosis (SSc), otherwise known as scleroderma. The primary endpoint of the study will be measured at 12 weeks, and will assess SSc disease severity using a combination of rheumatological, clinical, and physiological measures. This is the first study for bermekimab in rheumatology, which the Company believes has the potential to be a very important area of medicine for bermekimab therapy. The ongoing study will randomize patients 1:1 to receive either weekly subcutaneous injections of bermekimab or placebo. The study will also include an open label weekly bermekimab treatment regimen during weeks 13-24, where patients will continue to be evaluated using the same endpoints.

The Company reported that it strengthened its already considerable IP position during the quarter, including granting of important broad Canadian patents for bermkimab in the treatment of dermatological pathologies. In September the Company announced the Canadian Patent Office granted XBiotech Patent Number 56003542-6CA, covering the use of bermekimab in the treatment of inflammatory skin diseases. The patent describes studies showing that antibodies which specifically neutralize the activity of interleukin-1alpha (IL-1α), such as bermekimab, reduce skin inflammation and treat inflammatory skin diseases.

XBiotech plans to continue the development of its clinical pipeline along with research and development efforts to enable selection of drug candidates and research projects for further development in response to their preclinical and clinical success and commercial potential.

Risks

The Company continues to be subject to a number of risks common to companies in similar stages of development. Principal among these risks are the uncertainties of technological innovations, dependence on key individuals, development of the same or similar technological innovations by the Company’s competitors and protection of proprietary technology. The Company’s ability to fund its planned clinical operations, including completion of its planned clinical trials, is expected to depend on the amount and timing of cash receipts from future collaboration or product sales and/or financing transactions. The Company believes that its cash and cash equivalents of $40.3 million at September 30, 2019 will enable the Company to achieve some key inflection points, including clinical studies in certain indication(s), as well as on-going R&D efforts for the Company’s pre-clinical pipeline. Based on our research and development plans and our timing expectations related to the progress of our programs, we expect that our cash and cash equivalents as of September 30, 2019 will enable us to fund our operating expenses and capital expenditure requirements through September 30, 2020. We have based this estimate on assumptions that may prove to be inaccurate, and we could utilize our available capital resources sooner than we currently expect.

Revenues

To date, we have not generated any revenue. Our ability to generate revenue and become profitable depends on our ability to successfully commercialize our lead product candidate, bermekimab, or any other product candidate we may advance in the future.

Research and Development Expenses

Research and development expense consists of expenses incurred in connection with identifying and developing our drug candidates. These expenses consist primarily of salaries and related expenses, share-based compensation, the purchase of equipment, laboratory and manufacturing supplies, facility costs, costs for preclinical and clinical research, development of quality control systems, quality assurance programs and manufacturing processes. We charge all research and development expenses to operations as incurred.

Clinical development timelines, likelihood of success and total costs vary widely. We do not currently track our internal research and development costs or our personnel and related costs on an individual drug candidate basis. We use our research and development resources, including employees and our drug discovery technology, across multiple drug development programs. As a result, we cannot state precisely the costs incurred for each of our research and development programs or our clinical and preclinical drug candidates. From inception through September 30, 2019, we have recorded total research and development expenses, including share-based compensation, of $199.4 million. Our total research and development expenses for the three months and nine months ended September 30, 2019 were $4.5 million and $13.8 million, respectively, compared to $3.9 million and $10.9 million for the three months and nine months ended September 30, 2018, respectively. Share-based compensation accounted for $0.4 million and $1.0 million for the three months and nine months ended September 30, 2019, respectively, compared to $0.2 million and $0.5 million for the three months and nine months ended September 30, 2018, respectively.

Research and development expenses, as a percentage of total operating expenses for the three months and nine months ended September 30, 2019 were 74% and 77% compared to 77% and 73% for the three months and nine months ended September 30, 2018, respectively. The percentages, excluding share-based compensation, for the three months and nine months ended September 30, 2019 were 78% and 79%, compared to 79% and 76% for the three months and nine months ended September 30, 2018, respectively.

The clinical development costs may further increase going forward with potentially more advanced studies in the future as we evaluate our clinical data and pipeline.

Based on the results of our preclinical studies, we anticipate that we will select drug candidates and research projects for further development on an ongoing basis in response to their preclinical and clinical success and commercial potential. For research and development candidates in early stages of development, it is premature to estimate when material net cash inflows from these projects might occur.

General and Administrative Expenses

General and administrative expense consists primarily of salaries and related expenses for personnel in administrative, finance, business development and human resource functions, as well as the legal costs of pursuing patent protection of our intellectual property and patent filing and maintenance expenses, stock–based compensation, and professional fees for legal services. Our total general and administration expenses for the three months and nine months ended September 30, 2019 were $1.6 million and $4.2 million, respectively, compared to $1.2 million and $4.0 million for the three months and nine months ended September 30, 2018, respectively. Share-based compensation accounted for $0.4 million and $0.9 million for the three months and nine months ended September 30, 2019, respectively, compared to $0.2 million and $0.7 million for the three months and nine months ended September 30, 2018, respectively.

General and administrative expenses, as a percentage of total operating expenses for the three months and nine months ended September 30, 2019 were 26% and 23%, compared to 23% and 27% for the three months and nine months ended September 30, 2018, respectively. The percentages, excluding share-based compensation, for the three months and nine months ended September 30, 2019 were 22% and 20%, compared to 21% and 24% for the three months and nine months ended September 30, 2018, respectively.

Critical Accounting Policies

The preparation of financial statements in conformity with generally accepted accounting principles requires us to make judgments, estimates and assumptions in the preparation of our consolidated financial statements and accompanying notes. Actual results could differ from those estimates. We believe there have been no significant changes in our critical accounting policies as discussed in our Annual Report on Form 10-K for the year ended December 31, 2018.

Results of Operations

Revenue

We did not record any revenue during the three months and nine months ended September 30, 2019 and 2018.

Expenses

Research and Development

Research and Development costs are summarized as follows (in thousands):

Three Months Ended September 30, 2019 2018 Increase (Decrease) % Increase (Decrease)
Salaries and related expenses $1,291 $1,017 $274 27%
Laboratory and manufacturing supplies 1,048 528 520 98%
Clinical trials and sponsored research 355 447 (92) -21%
Share-based compensation 386 224 162 72%
Other 1,453 1,724 (272) -16%
Total $4,533 $3,940 $592 15%

20

Nine Months Ended September 30, 2019 2018 Increase (Decrease) % Increase (Decrease)
Salaries and related expenses $3,640 $3,088 $552 18%
Laboratory and manufacturing supplies 3,634 1,165 2,469 212%
Clinical trials and sponsored research 852 1,041 (189) -18%
Share-based compensation 972 474 498 105%
Other 4,655 5,114 (459) -9%
Total $13,753 $10,882 $2,871 26%

We do not currently track our internal research and development costs or our personnel and related costs on an individual drug candidate basis. We use our research and development resources, including employees and our drug discovery technology, across multiple drug development programs. As a result, we cannot state precisely the costs incurred for each of our research and development programs or our clinical and preclinical drug candidates.

Research and development expenses increased 15% to $4.5 million for the three months ended September 30, 2019 compared to $3.9 million for the three months ended September 30, 2018. Research and development expenses increased 26% to $13.8 million for the nine months ended September 30, 2019 compared to $10.9 million for the nine months ended September 30, 2018.

The three month increase in research and development expenses was mainly due to a $0.5 million increase of laboratory and manufacturing supplies, related to the clinical drug manufacturing for the clinical trial opened in the third quarter of the year. Clinical trials and sponsored research expense decreased due to the completion of two clinical trials started in 2018 and the newly opened clinical trial hasn’t fully executed. In addition, there was an increase in salary and related expenses and share-based compensation due to the increase of our research and development workforce from 44 to 53. Also, the increase was offset by the $0.3 million decrease in facility expense in other fees, because of the full termination of the lease associated with the office building on Riverside in Austin Texas.

Compared to the nine months ended September 30, 2018, the research and development expense increase in the nine months ended September 30, 2019 was primarily caused by the increase of laboratory and manufacturing supplies for the clinical trial opened in the third quarter of the year. Labor costs and share-based compensation also increased due to the growing size of the research and development workforce.

General and Administrative

General and administrative costs are summarized as follows (in thousands):

Three Months Ended September 30, 2019 2018 Increase (Decrease) % Increase (Decrease)
Salaries and related expenses $397 $191 $206 108%
Patent filing expense 173 208 (35) -17%
Share-based compensation 411 215 196 91%
Professional fees 221 210 11 5%
Other 376 351 25 7%
Total $1,578 $1,175 $403 34%

21

Nine Months Ended September 30, 2019 2018 Increase (Decrease) % Increase (Decrease)
Salaries and related expenses $862 $899 $(37) -4%
Patent filing expense 542 609 (67) -11%
Share-based compensation 881 712 169 24%
Professional fees 761 553 208 38%
Other 1,123 1,231 (108) -9%
Total $4,169 $4,004 $165 4%

General and administrative expenses increased 34% to $1.6 million for the three months ended September 30, 2019 compared to $1.2 million for the three months ended September 30, 2018. General and administrative expenses increased 4% to $4.2 million for the nine months ended September 30, 2019 compared to $4.0 million for the nine months ended September 30, 2018.

The three months increase was primarily related to a $0.2 million increased in salaries and related expense due to the $228 thousand bonus paid to the Chief Executive Officer in July 2019. Share-based compensation increased due to the 300 thousand stock options granted to the Chief Executive Officer in 2019 compared to 200 thousand in 2018.

Compared to the nine months ended September 30, 2018, , the general and administrative expense slightly increased in the nine months ended September 30, 2019 was primarily caused by the increase in professional fees due to services for underwriter agreement in Q2. Share-based compensation increased due to the stock options granted to the Chief Executive Officer and employees.

Other income (loss)

The following table summarizes other income (loss) (in thousands):

Three Months Ended September 30, 2019 2018 Nine Months Ended September 30, 2019 2018
Interest income 250 100 379 270
Other income - - 10 -
Foreign exchange (loss) (289) (36) (333) (411)
Total $(39) $64 $56 $(141)

The interest income for the three months and nine months ended September 30, 2019 and 2018 was mainly from the interest generated from the Company’s Canadian bank account. Foreign exchange loss was mainly due to the fluctuation between US dollar and Euro in the three months and nine months ended September 30, 2019 compared to the three months and nine months ended September 30, 2018.

Liquidity and Capital Resources

Our cash requirements could change materially as a result of the progress of our research and development and clinical programs, licensing activities, acquisitions, divestitures or other corporate developments.

Since our inception on March 22, 2005 through September 30, 2019, we have funded our operations principally through public offerings and the private placement of equity securities, which have provided aggregate cash proceeds of approximately $296.3 million. The following table summarizes our sources and uses of cash (in thousands):

Net cash (used in) provided by: Nine Months Ended September 30, 2019 2018
Operating activities $(14,524) $(11,421)
Investing activities (198) (114)
Financing activities 38,924 201
Effect of foreign exchange rate on cash and cash equivalents 313 415
Net change in cash and cash equivalents $24,515 $(10,919)

22

During the nine months ended September 30, 2019 and 2018, our operating activities used net cash of $14.5 million and $11.4 million, respectively. The use of net cash in each of these periods primarily resulted from our net losses. The increase in net loss from operations for the nine months ended September 30, 2019 as compared to the nine months ended September 30, 2018 was mainly due to the increase in laboratory and manufacturing supplies.

During the nine months ended September 30, 2019 and 2018, our investing activities used net cash of $198 thousand and $114 thousand, respectively. The use of cash was for the purchase of new research and development equipment.

During the nine months ended September 30, 2019 and 2018, our financing activities provided net cash proceeds of $38.9 million and $0.2 million, respectively. During the nine months ended September 30, 2019, the Company sold 4.8 million shares under the Common Shares Purchase Agreement with Piper Jaffray & Co for net proceeds of approximately $37.5 million. Employees exercised stock options to purchase a total of 318 thousand shares of our common stock for approximately $1.2 million in net proceeds. In this period, the Company also collected $0.3 million of its subscription receivable balance. During the nine months ended September 30, 2018, employees exercised stock options to purchase a total of 81 thousand shares of our common stock for approximately $0.2 million in net proceeds.

We expect to continue to incur substantial operating losses in the future. We will not receive any product revenue until a drug candidate has been approved by the FDA, EMA or similar regulatory agencies in other countries and successfully commercialized, or other potential business development transaction.. As of September 30, 2019, our principal sources of liquidity were our cash and cash equivalents, which totaled approximately $40.3 million.

Off-Balance Sheet Arrangements

Since inception, we have not engaged in any off-balance sheet activities, including the use of structured finance, special purpose entities or variable interest entities.

Market risk

As filed, 308 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

The Company is not currently exposed to material market risk arising from financial instruments, changes in interest rates or commodity prices, or fluctuations in foreign currencies. The Company has no need to hedge against any of the foregoing risks and therefore currently engages in no hedging activities.

Controls and procedures

As filed, 1,804 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

Management's Evaluation of our Disclosure Controls and Procedures

As of the end of the period covered by this Quarterly Report on Form 10-Q, an evaluation was carried out by the Company’s management, with the participation of the Chief Executive Officer and Principal Financial Officer, of the effectiveness of the Company’s disclosure controls and procedures, as defined in Rule 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934. Based on such evaluation, the Chief Executive Officer and Principal Financial Officer concluded that the Company’s disclosure controls and procedures are effective to ensure that information required to be disclosed in the reports the Company files or furnishes under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and regulations, and are operating in an effective manner.

Changes in Internal Control Over Financial Reporting

There was no change in our internal control over financial reporting that occurred during the third quarter of the year ended December 31, 2019 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

Limitations on Effectiveness of Controls and Procedures

In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that management is required to apply judgment in evaluating the benefits of possible controls and procedures relative to their costs.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2019-09-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Research and development3 months2019-07-01 to 2019-09-30$4.5mus-gaap:ResearchAndDevelopmentExpense
Research and development9 months2019-01-01 to 2019-09-30$13.8mus-gaap:ResearchAndDevelopmentExpense
Operating income3 months2019-07-01 to 2019-09-30−$6.1mus-gaap:OperatingIncomeLoss
Operating income9 months2019-01-01 to 2019-09-30−$17.9mus-gaap:OperatingIncomeLoss
Net income3 months2019-07-01 to 2019-09-30−$6.2mus-gaap:NetIncomeLoss
Net income9 months2019-01-01 to 2019-09-30−$17.9mus-gaap:NetIncomeLoss
Diluted EPS9 months2019-01-01 to 2019-09-30−$0.47us-gaap:EarningsPerShareBasicAndDiluted
Operating cash flow9 months2019-01-01 to 2019-09-30−$14.5mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure9 months2019-01-01 to 2019-09-30$198.0kus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Cash and equivalentsAt period end2019-09-30$40.3mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2019-09-30$40.9mus-gaap:AssetsCurrent
Total assetsAt period end2019-09-30$66.6mus-gaap:Assets
Current liabilitiesAt period end2019-09-30$2.0mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2019-09-30$2.0mus-gaap:Liabilities
Shareholders' equityAt period end2019-09-30$64.6mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001171843-19-007437. Last ingested by Listed: Nov 14, 2026, 18:14 ET. Listed shows no prices and gives no investment advice.